These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39061232)

  • 1. LncRNA LOC730101 Promotes Darolutamide Resistance in Prostate Cancer by Suppressing miR-1-3p.
    Zhou T; Nguyen S; Wu J; He B; Feng Q
    Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly expressed lncRNA LOC730101 promotes lung cancer cell growth through Wnt canonical pathway.
    Liu L; Zhang Y; Cao W
    Biochem Biophys Res Commun; 2017 Nov; 493(2):992-997. PubMed ID: 28943432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA LOC730101 promotes osteosarcoma cell survival under energy stress.
    Cheng G; Li B; Sun X; Cao Z; Zhang G; Zhao Z; Zhao Y; Yu Q; Liu W
    Biochem Biophys Res Commun; 2018 Jan; 496(1):1-6. PubMed ID: 29253564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide.
    Shiota M; Ushijima M; Tsukahara S; Nagakawa S; Blas L; Takamatsu D; Kobayashi S; Matsumoto T; Inokuchi J; Eto M
    Drug Resist Updat; 2023 Sep; 70():100990. PubMed ID: 37478518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
    Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
    Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
    Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
    Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darolutamide For Castration-Resistant Prostate Cancer.
    Bastos DA; Antonarakis ES
    Onco Targets Ther; 2019; 12():8769-8777. PubMed ID: 31695432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Non-coding RNA SNHG17 Promotes Cell Proliferation and Invasion in Castration-Resistant Prostate Cancer by Targeting the miR-144/CD51 Axis.
    Bai M; Lei Y; Wang M; Ma J; Yang P; Mou X; Dong Y; Han S
    Front Genet; 2020; 11():274. PubMed ID: 32351538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
    Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
    Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA VPS9D1-AS1 regulates miR-187-3p/fibroblast growth factor receptor-like 1 axis to promote proliferation, migration, and invasion of prostate cancer cells.
    Wu C; Chen J; Wang D
    Chin J Physiol; 2023; 66(5):295-305. PubMed ID: 37929340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Non-Coding RNA AC008972.1 as a Novel Therapeutic Target for Prostate Cancer.
    Zeng Q; Liu J; Wu Q; Song R; Miao W; Ma Y; Yang H
    Cancer Biother Radiopharm; 2024 May; 39(4):291-305. PubMed ID: 36094409
    [No Abstract]   [Full Text] [Related]  

  • 16. The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1.
    Huang S; Liao Q; Li W; Deng G; Jia M; Fang Q; Ji H; Meng M
    Bull Cancer; 2021 Apr; 108(4):359-368. PubMed ID: 33743960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
    Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K
    Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.
    Fujmoto S; Fujita K; Nishimoto M; Hamaguchi M; Kuwahara K; Hashimoto M; Adomi S; Minami T; Nozawa M; Yoshimura K; Uemura H
    Cancer Med; 2023 Feb; 12(3):3176-3179. PubMed ID: 36043427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
    Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
    Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.